首页> 外文期刊>Clinical ophthalmology >Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
【24h】

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy

机译:地塞米松0.4mg缓释肿瘤内插入眼科炎症和眼科手术后的疼痛:设计,开发和疗法

获取原文
           

摘要

Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.
机译:炎症和疼痛是眼科手术后的两个普遍存在的结果。皮质类固醇被广泛促使以控制手术后炎症和疼痛的核心处理。不合适的患者坚持术后滴眼症方案,局部滴眼的有限的生物利用度,以及许多这些滴眼液中使用的防腐剂的负面影响,对术后疼痛和炎症进行了新的疗法对新的疗法进行了强烈的案例。对文献的审查将重点关注颅内缓释的地塞米松(Dexxtenza,Oculary Therapeutix,Bedford,Ma,USA)的作用,用于治疗眼睑炎症和疼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号